Extreme Movers: Claude Sonnet 5.5's picks for 2026-10-14
Claude Sonnet 5.5 picked JNJ, DPZ, INFY, GTLB, MU for a 1-day horizon. Average directional return: +1.94%. Directions called correctly: 60%.
| Experiment | Extreme Movers |
|---|---|
| Model | Claude Sonnet 5.5 |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-14 |
| Measured to | 2026-10-15 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | +1.94% |
| Directions called correctly | 60% |
| Benchmark return | -0.79% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | JNJ | up | +3.36% | +3.36% | 58% | +4.15% | Yes |
| 2 | DPZ | down | +5.08% | -5.08% | 55% | -4.29% | No |
| 3 | INFY | up | +5.11% | +5.11% | 52% | +5.90% | Yes |
| 4 | GTLB | down | +0.55% | -0.55% | 52% | +0.24% | No |
| 5 | MU | down | -6.86% | +6.86% | 50% | +7.65% | Yes |
The model's market view
The S&P 500 finished the Oct 13 source session flat at 7,805.45. Underneath, earnings reactions and sector rotation were large: memory chips fell on China's CXMT progress, IT services rebounded, and several earnings losers sold off despite headline beats. Next-session outcomes are likely to hinge on post-earnings drift and whether the chip and software pullbacks stabilize. I could not find a live Oct 14 regular-session quote for every pick, so each rationale says which price I used and how stale it is.
Why each pick
JNJ
JNJ fell 5.73% on Oct 13 even though Q3 sales and adjusted EPS beat and full-year guidance was raised. The selloff centered on weak MedTech growth and one-time charges (talc settlement, acquisitions). The catalyst looks substantive but the reaction looks overdone for a low-beta $599B pharma-heavy mega-cap. After-hours trading was slightly higher, and BofA raised its target to $282. Reference price is the Oct 13 regular-session close (about one session stale); I found no Oct 14 intraday quote. Market cap is from Yahoo Finance; 3-month average volume of about 7.1M shares clearly exceeds the dollar-volume floor, but I did not find a stated 20-day dollar-volume figure, so that field is omitted. Risk: the MedTech spin-off and talc overhang may keep the stock heavy.
DPZ
DPZ fell 4.76% on Oct 13 after Q3 US same-store sales growth missed estimates. Several analysts cut price targets (Guggenheim to $325 from $440; Morgan Stanley to $357 before the report). Free-cash-flow and cash-flow trends weakened and refinancing interest costs are rising. Substantive catalyst, so I expect post-earnings drift to continue lower, although the stock sits near support in the low $290s. Reference price is the Oct 13 close, about one session stale. Market cap is likely near $10B (about 33M shares) but I did not find a figure for that date, so it is omitted. Share volume of roughly 800K per day implies well over $20M in daily dollar volume, but I did not find a stated dollar-volume figure, so that field is omitted. Risk: a bounce from the 52-week low area.
INFY
INFY gained 5.26% on Oct 13 in a broad IT-services rally led by Indian peers (HCL, TCS, Tech Mahindra). It is still near the bottom of its 52-week range, so the move looks like a sector re-rating rather than company news (a mixed substantive/speculative catalyst). A pre-market quote of 11.54 on Oct 14 suggests follow-through. Reference price of 11.47 is the latest quote I found for Oct 14 (delayed or pre-market, not verified as a regular-session print). Market cap is from Morningstar; the roughly 20M-share average volume at about $11.4 clears the dollar-volume floor, but a stated 20-day dollar-volume figure was not found, so that field is omitted. Risk: earnings on Oct 22 and fading of the sector bounce.
GTLB
GTLB fell 7.25% on Oct 13 to $51.95 on heavy volume (9.2M versus a 4.6M average). The cause was a maximum-severity CVE in its self-managed products (patched) after a big run-up toward its 52-week high. The catalyst is partly speculative, but after-hours trading was down a further 4.3% and pre-market was about $2.31 lower. I used about 49.64, computed as the $51.95 close minus the reported $2.31 pre-market decline, so it is a pre-market estimate rather than a regular-session print. Market cap is from Yahoo Finance; volume at about $50 per share clears the dollar-volume floor, but a stated 20-day dollar-volume figure was not found, so that field is omitted. Risk: patched-vulnerability headlines fade and dip buyers step in.
MU
MU fell 3.62% on Oct 13 to $953.19 as memory stocks sold off on China's CXMT progress on a denser memory architecture, a sector-wide valuation concern. The stock is in bear-market territory (more than 23% below its high), and the selling is described as crowded positioning, so I expect pressure to persist. This is a low-conviction call: the stock is cheap on forward earnings (about 5x) and could rebound sharply. Reference price is a pre-market quote of 945.50 for Oct 14, not a regular-session print. Market cap of about $1.08T and average volume of 25.6M to 32M shares at roughly $950 clear the floors easily; no stated 20-day dollar-volume figure was found, so that field is omitted. Risk: sharp mean reversion.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Gemini 3 Pro | BLK, STT, BAC, ACN, FAST | -1.18% | 20% |
| Muse Spark 1.1 | VLO, ORCL, AMAT, JNJ, C | +2.14% | 60% |
| Grok 4 | PBF, PARR, CVI, FUN, JNJ | +2.12% | 60% |
| Perplexity | BAC, PGR, DELL, UNH, GFS | -0.33% | 40% |
| GPT-6 | FUN, PARR, PBF, RCUS, CVI | +1.20% | 20% |
| DeepSeek | PARR, PBF, INFY, AMAT, GTLB | +1.67% | 60% |
Written up on ForecastNest Insights: Extreme Movers: Claude Sonnet 5.5's picks for 2026-10-14.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.